二肽基肽酶-4 抑制剂与血管性水肿：类效应？
Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?
机构信息
Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
出版信息
Diabet Med. 2013 Apr;30(4):e149-50. doi: 10.1111/dme.12134.
BACKGROUND
Dipeptidyl peptidase-4 (DPP-4) inhibitors have been reported to be generally well tolerated. However, angioedema has been reported as one of the rare adverse events of these drugs.
CASE REPORT
We report a case in which angioedema induced by vildagliptin disappeared after changing to another DPP-4 inhibitor, alogliptin.
DISCUSSION
Our case suggests that there is a difference in the risk of angioedema among DPP-4 inhibitors. To clarify this possibility, further investigation on the risk of angioedema among DPP-4 inhibitors is warranted.
背景
二肽基肽酶-4（DPP-4）抑制剂通常被认为具有良好的耐受性。然而，血管性水肿已被报道为这些药物的罕见不良反应之一。
病例报告
我们报告了一例因维格列汀引起的血管性水肿，在改用另一种 DPP-4 抑制剂阿格列汀后消失。
讨论
我们的病例提示 DPP-4 抑制剂之间发生血管性水肿的风险存在差异。为了阐明这种可能性，有必要进一步研究 DPP-4 抑制剂发生血管性水肿的风险。
Zotero 插件